Business Insider5 天
Vertex Pharmaceuticals: Strong Buy Rating Driven by Journavx Approval and Market Expansion ...
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target to $591.00. Leverage the power of TipRanks' Smart ...
Business Insider5 天
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare sector as a whole. This time last year, the biotech ...
The Motley Fool6 天
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...
FXStreet1 天
Economic calendar
The US economic calendar is the most important one since the country is the largest world economy. The most important indicators mainly impact the price of the dollar, having important effects in ...
STAT5 天
The first shot taken at Medicaid, and Optum’s wellness visit ad
UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...
CNET15 小时
Here's How to See Six Planets in a Spectacular Planet Parade This Weekend
2025 is starting off with a bang for skygazers, with a planet parade now visible in the night sky. A planet parade is when several of our solar system's planets are visible in the night sky at the ...